BALTIMORE, MD--(Marketwired - Jul 2, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that Plandaí Biotechnology Inc. (
Professional and amateur athletes alike are constantly seeking an advantage to fight muscle fatigue and improve physical performance. This has spurred a growth in sports drinks and other 'nutraceutical' products as the athletic-minded consumer looks for an advantage via better performance. For example, in 2012, Global Industry Analysts (GIA) released a comprehensive report that forecast the consumption of sports and nutrition foods and drinks to be a $55 billion market in the U.S. alone by 2018.
Plandaí Biotechnology Inc.'s (
In fact, the unique product contains all of vitamins A & C, bioflavonoids, (especially Hesperidin and Rutin), limonoids (especially limonin and nomilin), and numerous minerals, including potassium and pectin. There is extensive research showing that citrus bioflavonoids have tremendous anti-inflammatory properties. Moreover previous third-party testing has shown that athletes taking a high-dosage citrus limonoid complex have experienced faster post-work out recovery and the virtual elimination of muscle pulls.
The Company plans to conduct future studies and trials for this product and, once it receives approval and is introduced to the consumer, it will be marketed to include all of the major benefits including enhanced athletic performance. Clearly, Plandaí's next generation delivery system and high absorption advantages will give Plandai a superior edge over competitors and presents substantial revenue opportunities in a huge vertical market.
Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (